Albertsons (ACI) reported earnings on Mon 18 Oct 21 (b/o)

 ** charts after earnings **

Albertsons increases quarterly dividend to $0.12/share from $0.10/share

Albertsons beats by $0.19, beats on revs; raises FY22 EPS above consensus

• Reports Q2 (Aug) earnings of $0.64 per share, $0.19 better than the S&P Capital IQ Consensus of $0.45; revenues rose 4.7% year/year to $16.51 bln vs the $15.85 bln S&P Capital IQ Consensus.
• Co issues upside guidance for FY22, sees EPS of 2.50-2.60 vs. $2.33 S&P Capital IQ Consensus (previously $2.20 to $2.30 per share).
  • Identical sales in fiscal 2021 in the range of (2.5%) to (3.5%) (previously (5%) to (6%)), representing two-year stacked growth of 13.4% to 14.4% (previously 10.9% to 11.9%)

Translate Bio (TBIO) to be acquired by Sanofi (SNY) for $3.2 billion

• Sanofi will pay $38 per share in cash, or $3.2 billion
• Translate Bio specializes in messenger RNA technology, the same used by Moderna and BioNTech in their Covid-19 vaccines.
• IPO on  June 28, 2018

 

 

 

 

Already partners, in June 2018 Sanofi and Translate Bio entered into a collaboration and exclusive licence agreement to develop mRNA vaccines, which was further expanded in 2020 to broadly address current and future infectious diseases.

Under the collaboration, there are two ongoing mRNA vaccine clinical trials: the COVID-19 vaccine Phase 1/2 study (with results expected in Q3 2021) and the mRNA seasonal influenza vaccine Phase 1 trial (with results due in Q4 2021).

The acquisition of Massachusetts-based Translate Bio will also help fast track Sanofi’s plans for its recently announced mRNA Centre of Excellence.

Desktop Metal (DM) reported earnings on Mon 17 May 21 (a/h)

• 2020 IPO: Desktop Metal, Inc. began trading on the NYSE on 12/10/20 via a reverse merger with special purpose acquisition company (SPAC) Trine Acquisition Corp. 

 

3D printing company Desktop Metal (NYSE:DM) delivers a mixed Q1 report.

• Revenue was up 234% on the year to $11.31M, about $1.4M ahead of consensus estimates. The $0.25 loss per share was $0.13 worse than expected.
• Non-GAAP gross profit improved $3.3M on the year to a positive $600,000.
• Cash and equivalents totaled $572.2M at the end of the quarter.
• The full-year outlook includes revenue of over $100M (consensus: $100.7M), exiting the year with an annualized revenue run rate of $160M. Adjusted EBITDA loss is expected at $60-70M.

-=BrightView (BV) reported earnings on Tue 27 Nov 18 (a/h)

BrightView beats by $0.06, reports revs in-line; guides FY19 revs in-line

• Reports Q4 (Sep) earnings of $0.35 per share, $0.06 better than the S&P Capital IQ Consensus of $0.29; revenues rose 2.6% year/year to $581.8 mln vs the $585.99 mln S&P Capital IQ Consensus.
• Adjusted EBITDA increased 5.6% to $84.2 million, with a 40 bps Adjusted EBITDA margin improvement to 14.5%.
• Net cash provided by operating activities for the twelve months ended September 30, 2018 was $180.4 million, compared to $124.2 million for the prior year.
• Co issues in-line guidance for FY19, sees FY19 revs of $2.40-$2.47 bln vs. $2.43 bln S&P Capital IQ Consensus. Sees Adj EBITDA of $310-$318 mln.

Coupa Software (COUP) reported earnings Mon 5 Dec 2016 (a/h)

• COUP was previously used by Coupons.com (COUP)

** charts before earnings **

** charts after earnings **

Coupa Software beats by $0.25, beats on revs; guides Q4 EPS, revs above consensus :

• Reports Q3 (Oct) loss of $0.22 per share, excluding non-recurring items, $0.25 better than the Capital IQ Consensus of ($0.47); revenues rose 55.4% year/year to $35.44 mln vs the $31.1 mln Capital IQ Consensus.
• Co issues upside guidance for Q4, sees EPS of ($0.19-0.16), excluding non-recurring items, vs. ($0.23) Capital IQ Consensus Estimate; sees Q4 revs of $35.5-36 mln vs. $32.40 mln Capital IQ Consensus Estimate.